These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 25893174

  • 1. Thrombin-activatable fibrinolysis inhibitor Thr325Ile polymorphism and plasma level in breast cancer: A pilot study.
    Fawzy MS, Mohammed EA, Ahmed AS, Fakhr-Eldeen A.
    Meta Gene; 2015 Jun; 4():73-84. PubMed ID: 25893174
    [Abstract] [Full Text] [Related]

  • 2. Plasma thrombin-activatable fibrinolysis inhibitor levels and Thr325Ile polymorphism as a risk marker of myocardial infarction in Egyptian patients.
    Kamal HM, Ahmed AS, Fawzy MS, Mohamed FA, Elbaz AA.
    Acta Cardiol; 2011 Aug; 66(4):483-8. PubMed ID: 21894805
    [Abstract] [Full Text] [Related]

  • 3. Plasma thrombin-activatable fibrinolysis inhibitor levels and its Thr325Ile polymorphism in breast cancer.
    Chengwei X, Xiaoli M, Yuan Z, Li P, Shengjiang W, Chao Y, Yunshan W.
    Blood Coagul Fibrinolysis; 2013 Oct; 24(7):698-703. PubMed ID: 23624357
    [Abstract] [Full Text] [Related]

  • 4. [Study on the association of thrombin activatable fibrinolysis inhibitor and the Thr325Ile and Thr147Ala polymorphisms of its encoding gene CPB2 in patients with coronary heart disease].
    Xu CW, Wang LL, Wu XB, Zhao JJ, Du YM, Jiang CY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):438-42. PubMed ID: 18683146
    [Abstract] [Full Text] [Related]

  • 5. Thrombin activatable fibrinolysis inhibitor plasma levels and TAFI Thr325Ile genetic polymorphism in a cohort of Egyptian sickle cell disease patients and impact on disease severity.
    Hamdy M, Shaheen IA, Khallaf M, Selim YMM.
    Pediatr Blood Cancer; 2024 Jun; 71(6):e30959. PubMed ID: 38520679
    [Abstract] [Full Text] [Related]

  • 6. Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system.
    Zorio E, Castelló R, Falcó C, España F, Osa A, Almenar L, Aznar J, Estellés A.
    Br J Haematol; 2003 Sep; 122(6):958-65. PubMed ID: 12956767
    [Abstract] [Full Text] [Related]

  • 7. Genetic variations in the thrombin-activatable fibrinolysis inhibitor gene and risk of cardiovascular disease: a systematic review and meta-analysis.
    Shi J, Zhi P, Chen J, Wu P, Tan S.
    Thromb Res; 2014 Sep; 134(3):610-6. PubMed ID: 25042727
    [Abstract] [Full Text] [Related]

  • 8. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 9. Profibrinolytic effects of rivaroxaban are mediated by thrombin-activatable fibrinolysis inhibitor and are attenuated by a naturally occurring stabilizing mutation in enzyme.
    Garabon JJW, Boffa MB.
    J Thromb Thrombolysis; 2023 Aug; 56(2):283-290. PubMed ID: 37310666
    [Abstract] [Full Text] [Related]

  • 10. A functional single nucleotide polymorphism in the thrombin-activatable fibrinolysis inhibitor (TAFI) gene associates with outcome of meningococcal disease.
    Kremer Hovinga JA, Franco RF, Zago MA, Ten Cate H, Westendorp RG, Reitsma PH.
    J Thromb Haemost; 2004 Jan; 2(1):54-7. PubMed ID: 14717966
    [Abstract] [Full Text] [Related]

  • 11. The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study.
    de Bruijne EL, Gils A, Guimarães AH, Dippel DW, Deckers JW, van den Meiracker AH, Poldermans D, Rijken DC, Declerck PJ, de Maat MP, Leebeek FW.
    J Thromb Haemost; 2009 Jun; 7(6):919-27. PubMed ID: 19323787
    [Abstract] [Full Text] [Related]

  • 12. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study.
    Kozian DH, Lorenz M, März W, Cousin E, Mace S, Deleuze JF.
    Thromb Haemost; 2010 May; 103(5):976-83. PubMed ID: 20216989
    [Abstract] [Full Text] [Related]

  • 13. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.
    Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP.
    Thromb Haemost; 2003 Jul; 90(1):92-100. PubMed ID: 12876631
    [Abstract] [Full Text] [Related]

  • 14. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe.
    Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegård A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group.
    Arterioscler Thromb Vasc Biol; 2002 May 01; 22(5):867-73. PubMed ID: 12006404
    [Abstract] [Full Text] [Related]

  • 15. Thrombin-activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children.
    Emonts M, de Bruijne EL, Guimarães AH, Declerck PJ, Leebeek FW, de Maat MP, Rijken DC, Hazelzet JA, Gils A.
    J Thromb Haemost; 2008 Feb 01; 6(2):268-76. PubMed ID: 18021301
    [Abstract] [Full Text] [Related]

  • 16. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays.
    Guimarães AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC.
    Br J Haematol; 2004 Mar 01; 124(5):659-65. PubMed ID: 14871254
    [Abstract] [Full Text] [Related]

  • 17. Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions.
    Segev A, Hegele RA, Lau HK, Sparkes JD, Teitel JM, Chisholm RJ, Strauss BH.
    Thromb Res; 2004 Mar 01; 114(2):137-41. PubMed ID: 15306156
    [Abstract] [Full Text] [Related]

  • 18. [Prognosis value of thrombin activatable fibrinolysis inhibitor concentration and C1040T polymorphism in acute myocardial infarction treated with fibrinolysis].
    González FJ, Caturla JM, Fernández M, Carrasco R, Marco P, Sánchez J, Benlloch S.
    Med Intensiva; 2010 Nov 01; 34(8):513-22. PubMed ID: 20627371
    [Abstract] [Full Text] [Related]

  • 19. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study.
    Morange PE, Tregouet DA, Frere C, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Cambien F, Tiret L, Juhan-Vague I, Prime Study Group.
    J Thromb Haemost; 2005 Jul 01; 3(7):1503-10. PubMed ID: 15978108
    [Abstract] [Full Text] [Related]

  • 20. Thrombin-activatable fibrinolysis inhibitor (TAFI) levels and its polymorphism rs3742264 are associated with dyslipidemia in a cohort of Brazilian subjects.
    Santos IR, Fernandes AP, Carvalho MG, Sousa MO, Ferreira CN, Gomes KB.
    Clin Chim Acta; 2014 Jun 10; 433():76-83. PubMed ID: 24631134
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.